CHRS profile · all as-reported value updates
Coherus Oncology, Inc. (CHRS) as-reported value updates
Descriptive filing record — not investment advice. This page compares two SEC XBRL-filed values for the same fiscal period. It does not state why the values differ and is not a rating, score, or recommendation. See Disclaimer.
Reported values for the same fiscal period can differ between filings for many routine reasons: re-presentation for discontinued operations, adoption of new accounting standards, reclassifications, changes in rounding precision, and amendments. This ledger records that the filed values differ; it does not and cannot determine why. Both filings are linked below so the reader can consult the source.
Ledger table figure
| Metric | FY | Earliest XBRL-filed value | Currently on file | Difference | Difference % | Label | Filing links | Notes |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2024 | 266,960,000 | 26,389,000 | -240,571,000 | -90.11% | revised comparative figure | 0001558370-25-003126 0001104659-26-025308 | 2 filed observations examined for this concept and period. |
| Operating income | 2024 | -111,667,000 | -199,653,000 | -87,986,000 | -44.07% | revised comparative figure | 0001558370-25-003126 0001104659-26-025308 | 2 filed observations examined for this concept and period. |
| Stockholders' equity | 2017 | 31,824,000 | 30,535,000 | -1,289,000 | -4.05% | revised comparative figure | 0001564590-18-004947 0001558370-21-001829 | 3 filed observations examined for this concept and period. |